Polymeric gene delivery system

• US 6,262,034 B1
• Filed: 11/25/1997
• Issued: 07/17/2001
• Est. Priority Date: 03/15/1994
• Status: Expired due to Fees

• Current Assignee: Neurotech S.A. (LivaNova Plc)
• Original Assignee: Neurotech S.A. (LivaNova Plc)
• Inventors: Mathiowitz, Edith, Boekelheide, Kim, Jong, Yong Shik
• Primary Examiner(s): Nguyen, Dave Trong
• Application Number:
  US08/978,522
• Time in Patent Office: 1,330 Days
• Field of Search: 435/455, 435/69.1, 435/320.1, 435/325, 435/91.4, 514/44, 536/23.1, 424/468, 424/486, 424/484, 424/497
• US Class Current: 514/44.00R
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61K 9/1272 with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids with cholesterol as the only non-phosphatidyl surfactant A61K9/127; lipids as modifying agent A61K47/543
• CPC Class Codes: A61K 9/1647 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/2027 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Abstract

A means for obtaining efficient introduction of exogenous genes into a patient, with long term expression of the gene, is disclosed. The gene, under control of an appropriate promoter for expression in a particular cell type, is encapsulated or dispersed with a biocompatible, preferably biodegradable polymeric matrix, where the gene is able to diffuse out of the matrix over an extended period of time, for example, a period of three to twelve months or longer. The matrix is preferably in the form of a microparticle such as a microsphere (where the gene is dispersed throughout a solid polymeric matrix) or microcapsule (gene is stored in the core of a polymeric shell), a film, an implant, or a coating on a device such as a stent. The size and composition of the polymeric device is selected to result in favorable release kinetics in tissue. The size is also selected according to the method of delivery which is to be used, typically injection or administration of a suspension by aerosol into the nasal and/or pulmonary areas. The matrix composition can be selected to not only have favorable degradation rates, but to be formed of a material which is bioadhesive, to further increase the effectiveness of transfer when administered to a mucosal surface.

Claims

1. A method of delivering naked DNA to a tissue site of a mammalian subject, said method comprising implanting directly, into said tissue site in said subject, a composition comprising:

(a) a preparation of microparticles between 1 and 300 μ

m in diameter, each of which preparation of microparticles comprises a synthetic, biocompatible, non-biodegradable polymeric matrix; and

(b) an effective amount of naked DNA contained within said matrix, wherein said amount of naked DNA is greater than 20 μ

g, and wherein the DNA contains a gene operably linked to a promoter, the nucleotide sequence of said gene being greater than thirty nucleotides in length;

wherein said DNA is released or diffused from said matrix after implantation over a period of at least three months.

2. The method of claim 1, wherein approximately 0.1-90% by weight of naked DNA is loaded into the polymeric matrix.

3. The method of claim 1, wherein the microparticles are approximately between 1 and 100 μ

m in diameter.

4. The method of claim 1, wherein the microparticles are approximately between 1 and 10 μ

m in diameter.

5. The method of claim 1, wherein the naked DNA is greater than one hundred nucleotides in length.

6. The method of claim 1, wherein the naked DNA comprises supercoiled DNA.

7. A composition for delivery of naked DNA into a cell comprising:

(a) a preparation of microparticles between approximately 1 and 300 μ

m in diameter, each of which preparation of microparticles comprises a synthetic polymeric matrix; and

(b) an effective amount of naked DNA contained within said matrix, wherein said amount of naked DNA is greater than 20 μ

g, and wherein the DNA contains a gene operably linked to a promoter, the nucleotide sequence of said gene being greater than thirty nucleotides in length;

wherein said DNA is released, or diffuses from said matrix after implantation over a period of at least three months.

8. The composition of claim 7, wherein the microparticles are between approximately 1 and 100 μ

m in diameter.

9. The composition of claim 7, wherein the microparticles are between approximately 1 and 10 μ

m in diameter.

10. The composition of claim 7, wherein the polymeric matrix is biodegradable.

11. The composition of claim 7, wherein the polymeric matrix is non-biodegradable.

12. The composition of claim 7, wherein approximately 0.1-90% by weight of the naked DNA is loaded into the polymeric matrix.

13. The composition of claim 7, wherein the naked DNA is greater than one hundred nucleotides in length.

14. The composition of claim 7, wherein the naked DNA comprises supercoiled DNA.